Pharmacology, Toxicology and Pharmaceutical Science
Heart Failure
100%
Acute Heart Failure
49%
Placebo
18%
Heart Failure with Reduced Ejection Fraction
17%
Biological Marker
15%
Congestive Heart Failure
14%
Brain Natriuretic Peptide
10%
Heart Failure with Preserved Ejection Fraction
10%
All Cause Mortality
8%
Vericiguat
7%
Diuretic Agent
7%
Dipeptidyl Carboxypeptidase Inhibitor
7%
Serelaxin
6%
Prevalence
6%
Creatinine
5%
Clinical Trial
5%
Angiotensin Receptor Antagonist
5%
Combination Therapy
5%
Erythropoietin
5%
Medicine and Dentistry
Heart Failure
71%
Acute Decompensated Heart Failure
34%
Ejection Fraction
14%
Heart Failure with Preserved Ejection Fraction
13%
Heart Failure with Reduced Ejection Fraction
11%
Kidney Function
10%
Biological Marker
10%
Cardiovascular System
9%
Congestive Heart Failure
8%
Hazard Ratio
8%
Heart Left Ventricle Ejection Fraction
7%
Placebo
7%
Combination Therapy
6%
Diuretic Agent
5%
Brain Natriuretic Peptide
5%
Amino Terminal Sequence
5%
Keyphrases
Heart Failure
27%
Acute Heart Failure
27%
Heart Failure with Preserved Ejection Fraction (HFpEF)
19%
Patients with Heart Failure
18%
Heart Failure Hospitalization
9%
Chronic Heart Failure
9%
Clinical Outcomes
8%
Confidence Interval
7%
Worsening Heart Failure
7%
Heart Failure Patients
7%
N-terminal Pro-brain Natriuretic Peptide (NT-proBNP)
7%
Placebo
7%
Vericiguat
6%
Hazard Ratio
6%
All-cause Mortality
6%
Preserved Ejection Fraction
6%
Heart Failure Trials
6%
Left Ventricular Ejection Fraction
6%
Renal Function
5%